This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Johns Hopkins University. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Jay Kalin: Innovator in Cancer and Neurodegenerative Disease Research
Introduction
Jay Kalin is a prominent inventor based in Baltimore, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of inhibitors for histone lysine-specific demethylase (LSD1) and histone deacetylases (HDACs). His work has the potential to impact the treatment of various diseases, including cancers and neurodegenerative disorders.
Latest Patents
Kalin holds a patent for a series of phenelzine analogs that are linked to an aromatic moiety. These compounds serve as inhibitors of LSD1 and/or one or more HDACs. The disclosed phenelzine analogs demonstrate potency and selectivity for LSD1 compared to MAO and LSD2 enzymes. They also exhibit significant changes in histone methylation, anti-proliferative activity in several cancer cell lines, and neuroprotection against oxidative stress. This innovative approach opens new avenues for treating conditions related to LSD1 and HDACs.
Career Highlights
Jay Kalin is affiliated with Johns Hopkins University, where he continues to advance his research in the field of cancer and neurodegenerative diseases. His work is characterized by a commitment to understanding the molecular mechanisms underlying these conditions and developing effective therapeutic strategies.
Collaborations
Kalin has collaborated with notable researchers such as Philip A. Cole and Shonoi Ming. These partnerships have enriched his research and contributed to the advancement of knowledge in the field.
Conclusion
Jay Kalin's innovative work in developing inhibitors for LSD1 and HDACs represents a significant advancement in biomedical research. His contributions have the potential to lead to new treatments for serious diseases, showcasing the importance of innovation in the medical field.